ArticleCancer2022

De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.

Yu-Wen Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.